ArticleInvestigative ophthalmology & visual science2026
YBX1 Modulated Corneal Neovascularization Induced by Alkali Burn via m5C-Dependent Regulation of the STAT3/HIF-1α/VEGFA Axis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Effective management of corneal neovascularization (CoNV) remains challenging, and the role of epitranscriptomic regulation, particularly N5-methylcytosine (m5C) modification, in this process remain incompletely defined. This study investigated the function and mechanism of the RNA-binding protein YBX1 in CoNV following alkali burn (AB). Methods: An AB-induced CoNV model was generated using C57BL/6 mice. In vitro, human umbilical vein endothelial cells (HUVECs) underwent hypoxia/reoxygenation (H/R). Multi-omics approaches including transcriptome sequencing, RNA immunoprecipitation sequencing, and m5C methylated RNA immunoprecipitation sequencing were used to identify YBX1 targets and their modification status. Functional assays assessed angiogenesis, apoptosis, and reactive oxygen species (ROS). The therapeutic potential of the YBX1 inhibitor Soyasaponin II (SII) was evaluated in vivo. Results: YBX1 was upregulated following AB and H/R. YBX1 knockdown suppressed HUVEC migration, tube formation, and ROS production, while promoting apoptosis; these effects were rescued by HIF-1α overexpression. Mechanistically, YBX1 activated the JAK1/STAT3 pathway and recognizes m5C-modified sequences on STAT3 and VEGFA mRNAs, enhancing their stability. In vivo, subconjunctival injection of SII attenuated CoNV, reduced inflammation, and modulated macrophage polarization. Conclusions: Our study unveils a novel epitranscriptomic mechanism in which YBX1 drives CoNV by regulating the stability of m5C-modified STAT3 and VEGFA mRNAs, thereby activating the JAK1/STAT3/HIF-1α axis. Inhibition of YBX1 with SII effectively counteracts this pathway, highlighting YBX1 as an attractive candidate for intervention against sight-threatening CoNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.